VIR - Vir Biotechnology Inc Stock Price & Dividend Safety Sector: Healthcare | Exchange: NASDAQ Global Select Current Price & Safety Score Price: 11.57 USD StockBonds Safety Grade: F Altman Z-Score (Bankruptcy Risk): 3.47 StockBond Score: 2.86 Company Description Vir Biotechnology Inc operates as an immunology company with commercialized products dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases Its pipeline features several key candidates Sotrovimab branded as Xevudy or VIR7832 a neutralizing monoclonal antibody for both treating and preventing SARSCoV2 infection VIR2218 and VIR3434 aimed at hepatitis B virus VIR2482 targeting the prevention of influenza A virus and VIR1111 designed to prevent human immunodeficiency virus The firm maintains a robust network of strategic partnerships and collaborations These include grant support from organizations like the Bill Melinda Gates Foundation and the National Institutes of Health It holds option and licensing arrangements with entities such as Brii Biosciences Limited and a collaboration and license agreement with Alnylam Pharmaceuticals Inc Further licensing relationships exist with The Rockefeller University and MedImmune Inc Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd alongside a research agreement with GlaxoSmithKline Biologicals SA Furthermore Vir has secured a manufacturing contract with Samsung Biologics CoLtd for SARSCoV2 antibodies and a clinical development partnership with Gilead Sciences Inc focused on chronic hepatitis B virus The company established in 2016 is headquartered in San Francisco California